Board summary
Key figures
42,430
Registered population
54.1% aged 18–64
28.7%
Aged 65+
ICB 19.0% · England 17.9%
3.0%
Ethnic minority (non-White)
1.0% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 31.9% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
7,687
Hypertension register
+8.41% in 3 yrs · England +5.60%
296
SMI register
7.9% of Cheshire West and Chester (LAD)'s
670
COPD register
Reviews +2.78% in 3 yrs
Forecast to 2030
9,413
Hypertension patients, 2030
+1,726 on today
70.9%
QRISK ≥20% on statins, 2030
+3.95pp over 3 yrs
7.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Under-80 blood pressure control is slipping.
Control fell 7.1% over three years (England +3.2%) to 67.5%, while QRISK ≥ 20% lipid therapy is 62.2% against 63.6% in England.
Asthma reviews and youth smoke checks lag.
Annual asthma reviews fell 5.2% (England +4.4%) to 66.0%, leaving about 960 patients unreviewed, while youth second-hand smoking recording is 69.9% (England 78.8%).
Non-frail diabetes glycaemic control improved strongly.
HbA1c control without frailty rose +12.4% over three years (England +4.4%) to 61.8% (England 57.4%), alongside 83.6% control in frail diabetes (England 81.9%).
Population, age and ethnicity
Patients aged 65+ comprise 28.7% of the list, 10.8 percentage points above England
Rural Alliance PCN serves 42,430 registered patients across six practices. The population is older than comparators: 28.7% (12,185 patients) are aged 65+, compared with 20.3% in Cheshire West and Chester, 19.0% in the ICB, and 17.9% in England. Patients aged 18-64 represent 54.1% and those aged 0-17 represent 17.2%. Area Census estimates show 97.0% White ethnicity against 95.3% in Cheshire West and Chester, 93.0% in the ICB, and 81.1% in England. Practice lists sum to 51,036, indicating unresolved denominator alignment, and Census ethnicity reflects catchment residents rather than GP registers.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire West and Chester (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire West and Chester LA) | 2,109 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.6% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire West and Chester LA) | 893 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire West and Chester LA) | 14.9 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 7.5, with 0.0% of registered patients in Core20 areas
The PCN sits at an average IMD decile of 7.5, reflecting lower deprivation than Cheshire West and Chester (6.3), the ICB (5.2), and England (5.5). Across all six practices, 0.0% of registered patients reside in Core20 areas (an estimated 0 patients), compared to 15.7% in Cheshire West and Chester, 31.9% in the ICB, and 21.0% in England. Practice average deciles include 6.5 at Laurel Bank Surgery and 7.8 at Tarporley Health Centre.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
296
SMI register
0.70% recorded prevalence
146
Learning disability register
0.35% recorded prevalence
8
Care homes, 316 beds
In the PCN catchment
9.6%
Provide unpaid care
Cheshire West and Chester (LAD), Census 2021
Recorded learning disability prevalence is 0.3% (146 patients) against 0.5% in Cheshire West and Chester, 0.6% in the ICB, and 0.6% in England; severe mental illness is 0.7% (296 patients) against 1.0%, 1.1%, and 1.0%. The catchment contains 8 care homes with 316 beds, though resident registrations are unconfirmed.
Severe mental illness: physical health checks
Recorded SMI blood pressure checks reach 87.3% (England 83.4%) and BMI checks reach 87.7% (England 82.1%). Smoking cessation support fell 3.2 pp from 2023 to 2025 (England +0.1 pp) to 90.7% (England 94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,687
Hypertension register
+8.41%
Register growth, 3 yrs
Cheshire West and Chester (LAD) +6.60% · England +5.60%
−5.19pp
BP control, under 80
≤140/90 · −2.64pp aged 80+
+1,726
More patients by 2030
Forecast 9,413 (21.47%)
Hypertension case-finding and control
Hypertension recorded prevalence is 18.3% (7,687 patients), above Cheshire West and Chester (17.0%), the ICB (16.8%) and England (15.2%). Although 89.8% of hypertensive patients had a recent blood pressure check, this reading rate fell 2.1% from 2023 to 2025 (England +3.6%). Blood pressure control among under-80s is 67.5%, trailing England (67.8%) after falling 7.1% from 2023 to 2025 (England +3.2%); overall treatment to threshold also fell 6.1% (England +3.6%). Denominators include personalised care adjustments.
Lipids and statins
For patients with QRISK ≥ 20%, 62.2% receive lipid-lowering therapy, below Cheshire West and Chester (63.8%) and England (63.6%), despite a 6.8% increase from 2023 to 2025 (England +6.2%). Meanwhile, CKD lipid therapy reaches 73.0% (England 70.3%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 94,646 | £1.30 | £1.71 | £1.86 | £123,040 |
| Cardiovascular (all), 2025 | 125,790 | £5.31 | £4.37 | £3.33 | £667,945 |
In 2026, the PCN prescribed 94,646 lipid-regulating items at £1.30 per item, below Cheshire West and Chester (£1.44), the ICB (£1.71) and England (£1.86), spending £53,002 less than at England's unit cost across 94,646 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.21%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.19%
Asthma prevalence, PCN 3-yr % change
Asthma reviews fell 5.2% from 2023 to 2025 (England +4.4%) to 66.0% (England 65.7%), leaving about 960 of 2,811 register patients without an annual review. For patients aged 6–19 with asthma, second-hand smoke recording is 69.9%, trailing England (78.8%) and Cheshire West and Chester (75.2%). Meanwhile, COPD reviews reached 79.0% (England 76.4%), with 670 patients on the register (1.6% prevalence versus 1.9% in England).
Cancer register and children's immunisation
Cancer prevalence is 6.3% (2,638 patients), above England (3.8%), consistent with an older demographic (28.7% aged 65+). Childhood immunisation exceeds national rates: MMR dose 2 reaches 94.0% (England 82.8%) and 6-in-1 at 12 months reaches 92.2% (England 91.0%). However, 6-in-1 coverage is 2.8 pp below the 95.0% target.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers were diagnosed at stage 1 or 2 (7,482 of 13,490), in line with England (55.3%) but below the 75.0% national ambition by 2028 by 19.5 pp. Reaching that ambition requires about 2,640 extra early-stage cases annually across the ICB. Known-stage share was 72.8%. RURAL ALLIANCE PCN has a cancer prevalence of 6.3% (2,638 patients), growing +12.0% over three years (England +9.0%). ICB stage data describes the wider system, not PCN performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026, Countess of Chester Hospital NHS Foundation Trust achieved 87.4% on the 28-day faster diagnosis standard, exceeding the 75.0% standard, the ICB (77.2%) and England (79.3%). For 31-day combined treatment, it achieved 93.5% against the 96.0% standard (ICB 95.7%, England 92.5%). Its 62-day standard was 83.3%, below the 85.0% standard by 1.7 pp, but above the ICB (76.2%), England (71.2%) and Mid Cheshire Hospitals NHS Foundation Trust (71.1%), while North Cheshire and Mersey NHS Foundation Trust reached 83.7%. Diagnostic 6+ week waits were 11.3% for MRI and 4.2% for CT, outperforming England (21.4% and 9.9%).
| Pathways within standard (%) | Countess of Chester | Mid Cheshire | North Cheshire and Mersey | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 87.37 | 79.95 | 80.21 | 77.25 | 79.32 |
| 31-day treatment (96%) | 93.48 | 86.21 | 98.17 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.28 | 71.12 | 83.67 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Countess of Chester | Mid Cheshire | North Cheshire and Mersey | England |
|---|---|---|---|---|
| MRI | 11.26 | 5.15 | 0.53 | 21.40 |
| CT | 4.18 | 1.09 | 2.32 | 9.92 |
| Echocardiography | 31.44 | 5.51 | 28.04 | 28.48 |
| Colonoscopy | 26.44 | 30.34 | 15.98 | 30.83 |
| Gastroscopy | 27.52 | 31.89 | 20.24 | 29.02 |
| All 15 DM01 tests | 20.16 | 12.72 | 6.34 | 23.14 |
| Community services activity | Cheshire West and Chester residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 47,655 | 541,280 |
| Referrals | 10,325 | 97,150 |
| Patients with a contact | 18,585 | 146,240 |
Community services (residents of Cheshire West and Chester), Jun 2026 (provisional). In the provisional Jun 2026 Community Services Dataset, adults aged 65 and over accounted for 52.7% of all community contacts for Cheshire West and Chester residents (25,095 of 47,655 contacts). Community service activity is captured at local-authority level rather than by individual PCN, indicating substantial older-age community caseload across the surrounding borough.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Drs Adey And Dancy | 115 | 0.0 | 99.4% | 78.9% | 99.4% |
| Laurel Bank | 111 | 0.0 | 92.4% | 81.2% | 97.7% |
| Tarporley | 108 | 0.0 | 68.1% | 75.6% | 93.2% |
| Bunbury Medical | 107 | 0.0 | 87.8% | 67.9% | 91.6% |
| Kelsall | 119 | 0.0 | 75.5% | 84.5% | 88.9% |
| Village Surgeries | 118 | 0.0 | 52.7% | 81.1% | 76.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 measures trail England over three years, while diabetes control improved
Fourteen of 25 tracked measures trail England's three-year change. The largest lags appear in routine long-term condition management: heart failure reviews fell 3.8% (England +8.7%, trailing by 12.5 points), under-80 blood pressure control fell 7.1% (England +3.2%), and asthma reviews fell 5.2% (England +4.4%). Conversely, non-frail diabetes HbA1c control rose 12.4% over three years (England +4.4%) to 61.8% (1,218 of 1,971 patients), and frail control reached 83.6% (254 of 304). Alcohol recording for psychosis rose 6.3 pp (England +5.4 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BP control, under 80
Hypertension treated to target
Asthma reviews
Hypertension BP reading
Diabetes HbA1c control
Diabetes statin (CVD)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire West and Chester (LAD) | Asset | PCN | Cheshire West and Chester (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 8 (316 beds) | n/a | Schools (catchment) | 65 | n/a |
| Children's centres | no data | 15 | Places of worship | 90 | 231 |
| Libraries | 2 | 16 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | n/a | 1 | Day centres (VCS) | 1 | 1 |
| Carers support groups (VCS) | 1 | 1 | Primary schools (LA maintained) | 17 | 70 |
| Primary academies | 11 | 46 | Special schools | 1 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension control and lipid recall
Under-80 BP control is 67.5% (England 67.8%), falling 7.1% from 2023 to 2025 (England +3.2%); QRISK ≥ 20% lipid therapy is 62.2% (England 63.6%). For discussion: run a pharmacist-led recall and titration review across practices for under-80 hypertensive patients above target and high-QRISK patients not on statins. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured asthma review and smoke recording
Asthma reviews fell 5.2% (England +4.4%) to 66.0%, leaving about 960 of 2,811 patients unreviewed; age 6-19 second-hand smoke recording is 69.9% (England 78.8%). For discussion: introduce a single asthma review template prompting second-hand smoke recording, paired with after-school review slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
COPD case-finding and smoking support
COPD prevalence is 1.6% (670 patients) versus 1.9% in England and 2.1% in Cheshire West and Chester, an unadjusted gap of +134 to +241 patients. For discussion: audit records for smokers and ex-smokers with repeat respiratory prescribing lacking a COPD code, and embed smoking cessation prompts. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult care coordination (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Alternative health equity assessment (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall review (p6) | Cancer register · Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Cancer referral and safety netting (p7) | Cancers diagnosed at stage 1 or 2 (All cancer sites) | — | ICB |
| Option 1 · Hypertension control and lipid recall (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured asthma review and smoke recording (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · COPD case-finding and smoking support (p12) | COPD register · COPD: QOF prevalence · Aged 65+ | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
